Kalydeco

Prior Authorization Request

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____
Request Initiated For: _____

1. What is the patient's diagnosis? ❑ Cystic fibrosis ❑ Other _____
2. What is the ICD-10 code? _____
3. Was genetic testing performed to detect a mutation in the cystic fibrosis transmembrane conductance regulator *CFTR* gene? ❑ Yes ❑ No
4. Was the test positive for any of the following mutations? ***Indicate below or mark "None of the above."***

❑ A455E	❑ E56K	❑ G1069R	❑ R117C	❑ S549R
❑ A1067T	❑ E193K	❑ G1244E	❑ R117H	❑ S945L
❑ D110E	❑ F1052V	❑ G1349D	❑ R347H	❑ S977F
❑ D110H	❑ F1074L	❑ K1060T	❑ R352Q	❑ S1251N
❑ D579G	❑ G178R	❑ L206W	❑ R1070Q	❑ S1255P
❑ D1152H	❑ G551D	❑ P67L	❑ R1070W	❑ None of the above
❑ D1270N	❑ G551S	❑ R74W	❑ S549N	

5. Will Kalydeco be used in combination with Orkambi (lumacaftor/ivacaftor)? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Kalydeco SGM - 7/2017.